<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250121064471N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-05-17</date_registration>
      <primary_sponsor>Saveh University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy of Ketamine-Paracetamol versus Fentanyl-Paracetamol versus Paracetamol Monotherapy for Acute Postoperative Pain Management Using Patient-Controlled Analgesia  in Patients Undergoing Femoral Fracture Fixation</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of Ketamine-Paracetamol versus Fentanyl-Paracetamol versus Paracetamol Monotherapy for Acute Postoperative Pain Management Using Patient-Controlled Analgesia  in Patients Undergoing Femoral Fracture Fixation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-05-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/89222</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation of patients to the groups will be done using stratified block randomization method. Patients will be stratified into four strata based on two variables: age (under 50 years and 50 years and above) and gender. Then, using R software and the blockrand package, a random allocation sequence with variable blocks will be generated for each stratum and placed in sealed, opaque envelopes. An independent observer will allocate eligible patients to one of three groups: intervention (ketamine-paracetamol, fentanyl-paracetamol) or control (paracetamol) based on this sequence. This method, by concealing the allocation sequence, will prevent bias in the group assignment process.

It is expected that other potential confounding variables such as duration of surgery and anesthesia, and body mass index will be balanced between the groups due to the randomization process; this will be confirmed by comparing the baseline characteristics of participants at the start of the study, Blinding description: This study is designed as a double-blind trial. The patients, treating physicians, and evaluating nurses will be unaware of the nature and pharmaceutical composition of the contents of the pain pumps. The pumps used will be completely identical in appearance and will only be identified by coded labels (A, B, and C). The key to these codes will be accessible only to the independent person responsible for preparing the medications and the data supervisor.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Patients undergoing femoral fracture surgery. Condition 2: Patients undergoing femoral fracture surgery.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group (fentanyl): In addition to receiving the standard pain control protocol (including paracetamol), this group will also receive fentanyl at a dose of 1 µg/kg. The complete contents of the pump will be prepared in a total volume of 100 mL, and the infusion rate will be 5 mL per hour, similar to the control group. Intervention 2: : Second intervention group (ketamine): In addition to receiving the standard pain control protocol (including paracetamol), this group will also receive ketamine at a dose of 0.3 mg/kg. The complete contents of the pump will be prepared in a total volume of 100 mL, and the infusion rate will be 5 mL per hour, similar to the control group. Intervention 3: This group will receive the standard pain control protocol. The pump contents will include paracetamol at a dose of 10 mg/kg, with the total volume adjusted to 100 mL using normal saline, and will be administered at an infusion rate of 5 mL per hour.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No further information available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahsa Hajimirza</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Saveh, Madar Square, beginning of Jomhuri Street, Saveh Faculty of Medical Sciences and Health Services</address>
        <city>Saveh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۹۱۹۶۷۶۶۵۱</zip>
        <telephone>+98 86 4850 1000</telephone>
        <email>mahhajimirza@gmail.com</email>
        <affiliation>Saveh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Saleh Sadri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Saveh, Madar Square, beginning of Jomhuri Street, Saveh Faculty of Medical Sciences and Health Services</address>
        <city>Saveh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۳۹۱۹۶۷۶۶۵۱</zip>
        <telephone>+98 86 4850 1000</telephone>
        <email>mahhajimirza@gmail.com</email>
        <affiliation>Saveh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with ASA physical status class I or II
Aged 20 to 50 years
Patients undergoing femoral fracture surgery
Patients undergoing general anesthesia
Provision of written informed consent by the patient to participate in the study
Absence of acute visual or hearing impairments that would interfere with the patient's ability to understand instructions or use a patient-controlled analgesia pump
No performance of any sensory-neural block during or after the surgery</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Substance abuse (opioids), alcohol, or psychotropic drugs
Allergy to study medications (ketamine, fentanyl, acetaminophen, etc)
Pregnancy or lactation
Patient's refusal to continue cooperation in the study
Liver dysfunction or elevated liver enzymes
History of seizures or psychiatric disorders
History of chronic pain or daily analgesic use (more than one week)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S72.9</hc_code>
      <hc_code>S72.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified fracture of femur</hc_keyword>
      <hc_keyword>Fracture of head and neck of femur</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group (fentanyl): In addition to receiving the standard pain control protocol (including paracetamol), this group will also receive fentanyl at a dose of 1 µg/kg. The complete contents of the pump will be prepared in a total volume of 100 mL, and the infusion rate will be 5 mL per hour, similar to the control group.</i_keyword>
      <i_keyword>: Second intervention group (ketamine): In addition to receiving the standard pain control protocol (including paracetamol), this group will also receive ketamine at a dose of 0.3 mg/kg. The complete contents of the pump will be prepared in a total volume of 100 mL, and the infusion rate will be 5 mL per hour, similar to the control group</i_keyword>
      <i_keyword>This group will receive the standard pain control protocol. The pump contents will include paracetamol at a dose of 10 mg/kg, with the total volume adjusted to 100 mL using normal saline, and will be administered at an infusion rate of 5 mL per hour</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1-Pain intensity: The patient's mean pain score will be measured using the Visual Analog Scale (VAS). This scale consists of a 10-centimeter line, with the endpoints labeled from 0 (no pain) to 10 (worst possible pain). Timepoint: The assessment time points include immediately after surgery and at 2, 6, 12, 18, and 24 hours post-surgery. Method of measurement: This scale consists of a 10-centimeter line, with the endpoints labeled from 0 (no pain) to 10 (worst possible pain).</prim_outcome>
      <prim_outcome>Sedation level: A trained nurse will assess and record the patient's sedation level immediately after surgery and at 2, 6, 12, 18, and 24 hours post-surgery using the Ramsay Sedation Scale (which measures sedation from 1: anxious and agitated or restless, to 6: no response to a painful stimulus) by observing the patient's condition. Timepoint: The assessment time points include immediately after surgery and at 2, 6, 12, 18, and 24 hours post-surgery. Method of measurement: will be assessed and recorded using the Ramsay Sedation Scale (ranging from 1: anxious and agitated to 6: no response to a painful stimulus) by observing the patient's condition.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Saveh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-12</approval_date>
        <contact_name>Ethics Committee of Saveh University of Medical Sciences</contact_name>
        <contact_address>The campus building of Saveh University of Medical Sciences is located at the first exit after the General and Revolutionary Courts building on Namaz Boulevard in Saveh Saveh Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
